Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), filed a Form 4 on September 15, 2026, disclosing the vesting of restricted stock units and a subsequent sale of shares on September 14, 2026.

Key Highlights

  • RSU conversion: 18,333 restricted stock units were converted to common stock on September 11, 2026, via transaction code M.
  • Shares sold: 9,943 shares of common stock were sold on September 14, 2026, at a price of $98.37 per share.
  • Sale purpose: According to the filing, the shares were sold to cover tax withholding obligations associated with the vesting of the restricted stock units.
  • Remaining ownership: Following both transactions, Bjerkholt directly beneficially owned 44,745 shares of common stock.
  • RSU vesting schedule: The restricted stock units vest in three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

Mirum Pharmaceuticals CFO Discloses RSU Vesting and Tax-Related Share Disposition

According to the Form 4 filed with the SEC on September 15, 2026, Eric Bjerkholt, identified in the filing as Chief Financial Officer of Mirum Pharmaceuticals, Inc., reported two transactions in the company's common stock. On September 11, 2026, 18,333 restricted stock units were converted (transaction code M) into shares of common stock, bringing his directly held shares to 54,688 following that transaction.

The filing disclosed that on September 14, 2026, Bjerkholt disposed of 9,943 shares at a price of $98.37 per share. The filing's explanation of responses states that these shares were "sold to cover tax withholding obligations associated with the vesting of restricted stock units," not as a discretionary open-market sale. After this disposition, his direct beneficial ownership stood at 44,745 shares of common stock.

Regarding the derivative securities table, the filing shows that the 18,333 restricted stock units that vested carried a derivative security price of $0 and that each restricted stock unit "represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer)." The filing notes the RSUs were granted with a vesting schedule of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023, meaning this conversion represents one installment of that schedule. Following the M-coded transaction, zero restricted stock units remained in this grant series, per the filing.

What Was Disclosed

The filing reported the vesting of 18,333 restricted stock units into common stock on September 11, 2026, and the sale of 9,943 shares at $98.37 on September 14, 2026, to satisfy tax withholding, leaving Bjerkholt with 44,745 directly held shares.